How to identify rituximab infusion reactions?

Rituximab (Rituximab) infusion solution The reaction is mainly caused by the release of cytokines in the body. Cytokines are immune system proteins in the body that help fight infection, but may lead to inflammatory reactions. Infusion reactions are a very common side effect of rituximab treatment, occurring in more than 10% to 25% of patients across all approved uses of rituximab. Although cytokines help fight infection, too much of them can be harmful to the body. Sometimes these cytokine-related infusion-related reactions can be serious or lead to death.

InfusionReactions may occur while receiving a rituximab infusion or within one day of receiving rituximab treatment. If you develop hives (red itchy welts) or rash, swelling of lips, tongue, throat, or face, sudden cough, shortness of breath during or after an infusion of rituximab >, trouble breathing or wheezing, dizziness, dizziness, palpitations, chest pain, please inform your doctor immediately.

Rituximab is a chimeric mouse/ human monoclonal antibody that binds to theCD20antigen. CD20is primarily expressed on the surface of anterior Blymphocytes and mature Blymphocytes, allowing rituximab to target and promote lysis of this specific cell type. In patients with non-Hodgkin's lymphoma, rituximab treatment depletes circulating and tissue BB cells. In one study of 166 patients, CD19-positive B cells were depleted within three weeks, and depletion persisted for up to 6-9 months in 83% of patients. bCellular levels began to recover at approximately 6 months and returned to normal 12 months after completion of treatment. Approximately 14% of patients with non-Hodgkin's lymphoma have serum levels of IgM or IgG that are below the normal range. If you want to get more quality information, please contactYaoDe,YaoDe will do its best to learn more about overseas high-quality drugs for you